How safe is switching antiepileptic drug manufacturers?
Crossref DOI link: https://doi.org/10.1038/s41582-018-0108-6
Published Online: 2018-12-04
Published Print: 2019-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Holtkamp, Martin
Text and Data Mining valid from 2018-12-04
Article History
First Online: 4 December 2018
Competing interests
: The author has received speaker’s honoraria and/or consultancy fees from Bial, Desitin, Eisai, LivaNova, Novartis and UCB.